Primary alimentary lymphoma with metastasis to the liver causing encephalopathy in a horse

A 23‐year‐old, 467‐kg Palomino mare was examined for evaluation of sudden onset severe ataxia and depression. The mare had been found down in a pasture and was unable to rise. She was observed, by her owner, to be normal 24 hours earlier. This mare had resided with this owner for approximately 1.5 years, had always lived out on pasture, and had experienced numerous episodes of colic since the time she was purchased. Recent reported feed changes included introduction of new hay. Upon arrival at the hospital, the mare was severely ataxic in all 4 limbs and extremely disoriented. She head‐pressed several times during the course of the evaluation and yawned repeatedly. The mare was tachycardic, with a heart rate of 98 beats per minute, and tachypneic, with a respiratory rate of 60 breaths per minute, and the mucous membranes were hyperemic and purple, with a capillary refill time of greater than 3 seconds. The mare was blind bilaterally, as indicated by absence of both menace and pupillary light responses. She had bilateral facial nerve paralysis and decreased hypoglossal nerve function. She was able to prehend, but was dysphagic with decreased tongue tone and movement. Analysis of the venous blood revealed metabolic acidosis and respiratory alkalosis with a normal pH of 7.38 (reference range 7.32–7.44), HCO₃ of 13 mEq/L (reference range 25–30 mEq/L), PCO₂ of 21.2 mmHg (reference range 36–46 mmHg), and BE of ‐12 mEq/L (reference range ‐1‐1 mEq/L).^a It also revealed a low blood urea nitrogen concentration of 8 mg/dL (reference range 11–27 mg/dL) and a high blood glucose concentration of 263 mg/dL (reference range 63–134 mg/dL).^a Both packed cell volume and total solids were high at 52% (reference range 32–53%), and 8 g/dL (reference range 5.8–7.7 g/dL), respectively. The blood ammonia concentration was 120 μmol/L (reference range 18–78 μmol/L)^b.     

Effects of lufenuron treatment in cats on the establishment and course of Microsporum canis infection following exposure to infected cats

OBJECTIVE: To determine effects of lufenuron treatment in cats on the establishment and course of Microsporum canis infection following exposure to infected cats. DESIGN: Experimental trial. ANIMALS: 24 healthy juvenile domestic shorthair cats. PROCEDURE: 8 cats were given lufenuron PO (133 mg/cat/mo, equivalent to a dose of 100 to 130 mg/kg [45 to 59 mg/lb] at the beginning of the study and 25 to 35 mg/kg [11 to 16 mg/lb] at the end of the study), and 8 were given lufenuron SC (40 mg every 6 months). The remaining 8 were used as untreated control cats. After 4 months, cats were challenged by the introduction of cats with mild, experimentally induced M canis infection into the rooms where cats were housed. Extent of resulting infections in the na?ve cats was monitored for 22 weeks by physical examination and fungal culture. RESULTS: All lufenuron-treated and control cats became infected with M canis. Cats treated with lufenuron had significantly lower infection scores, compared with control cats, during the early weeks following exposure, and there was a more prolonged initial progression phase of the infection. Once infections reached peak intensity, they resolved over similar periods in lufenuron-treated and control cats. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that oral or SC administration of lufenuron to cats, at the dosages used and under the conditions of this study, did not prevent establishment of dermatophytosis following exposure to infected cats. Infection was established more slowly among cats treated with lufenuron, but once established, infection resolved in approximately the same amount of time in lufenuron-treated as in control cats.     

Plasma evaluation for ivermectin in llamas (Lama glama) after standard subcutaneous dosing.

Plasma levels of the parasiticide ivermectin were studied by high-performance liquid chromatography in five llamas (Lama glama) after single 200 microg/kg s.c. injections. Ivermectin levels were undetectable in plasma samples drawn up to 4 wk after injection, suggesting that the dosage used was insufficient to reach therapeutic concentrations in this species.     

A novel signature-tagged mutagenesis system for Streptococcus suis serotype 2

Streptococcus suis is an economically important, zoonotic pathogen causing death and disease in swine. The objectives of this study were to develop a signature-tagged mutagenesis (STM) system for S. suis serotype 2 and to identify genes required for in vivo virulence. Identification of such candidate genes may lead to a better understanding of the pathogenesis of S. suis and may provide substrate for the discovery of new vaccines. A novel STM approach was designed to allow for a higher throughput assay of mutants using the Luminex xMAP system. Additionally, to speed the identification process, a direct genomic DNA sequencing method was developed that overcomes the problems associated with the presence of repetitive insertion sequences. Approximately 2600 mutants were screened through both mouse and caesarian-derived, colostrum-deprived (CDCD) pig models. The disrupted ORF was identified for each potential attenuated mutant, and mutants with distinct and unique mutated ORFs were analyzed individually for attenuation in mouse and CDCD pig models. A variety of genes were identified, including previously known genes essential to the virulence of other organisms, genes involved in capsule biosynthesis, a regulator of suilysin expression, and several conserved or predicted genes. Of the 22 mutants identified as attenuated in either animal model, eight insertion mutants caused no mortality in both mouse and pig models.